# INO-3107

Type: Product

Source: Healthcare Intelligence Brief — https://gethealthbrief.com/entity/ino-3107
Canonical HTML page: https://gethealthbrief.com/entity/ino-3107

## Timeline

- **2026-10-30**: PDUFA Date — Target date for FDA decision on INO-3107 accelerated approval.
- **2026-06-30**: Platform Modernization — LivePerson expects to complete its multiyear platform modernization.
- **2026-03-12**: BLA Acceptance — FDA accepts Inovio's BLA for INO-3107 under accelerated approval program.
- **2024-12-31**: Inovio Cash Position — Company ends the year with $94.1 million in cash.

## Recent coverage (1 stories)

### Inovio Faces FDA Hurdle for INO-3107 as LivePerson Scales Enterprise AI
2026-03-18 00:31:26 · Sentiment: Neutral · Impact: 6/10 · Sources: 3

Inovio Pharmaceuticals faces a critical regulatory juncture as the FDA accepts its BLA for INO-3107 while questioning its accelerated approval eligibility. Meanwhile, LivePerson is pivoting toward a unified AI architecture with the launch of its Syntrix platform, signaling a shift in how healthcare enterprises may manage patient engagement.
Full story: https://gethealthbrief.com/story/inovio-fda-liveperson-ai-briefing

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://gethealthbrief.com/guides/methodology for the full editorial methodology.